Modality
ERT
MOA
PARPi
Target
JAK2
Pathway
Wnt
CTCLThymoma
Development Pipeline
Preclinical
~Dec 2014
→ ~Mar 2016
Phase 1
~Jun 2016
→ ~Sep 2017
Phase 2
~Dec 2017
→ ~Mar 2019
Phase 3
Jun 2019
→ May 2031
Phase 3Current
NCT07690229
2,994 pts·CTCL
2019-06→2025-04·Terminated
NCT03979891
2,869 pts·Thymoma
2020-08→2025-02·Active
NCT03128068
781 pts·Thymoma
2022-07→2030-09·Active
+1 more trial
8,621 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-02-191.1y agoPh3 Readout· Thymoma
2025-04-1412mo agoPh3 Readout· CTCL
2030-09-014.4y awayPh3 Readout· Thymoma
2031-05-255.1y awayPh3 Readout· CTCL
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Termina…
P3
Active
P3
Active
P3
Termina…
Catalysts
Ph3 Readout
2025-02-19 · 1.1y ago
Thymoma
Ph3 Readout
2025-04-14 · 12mo ago
CTCL
Ph3 Readout
2030-09-01 · 4.4y away
Thymoma
Ph3 Readout
2031-05-25 · 5.1y away
CTCL
ActiveTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07690229 | Phase 3 | CTCL | Terminated | 2994 | UPCR |
| NCT03979891 | Phase 3 | Thymoma | Active | 2869 | HbA1c |
| NCT03128068 | Phase 3 | Thymoma | Active | 781 | 6MWD |
| NCT08235057 | Phase 3 | CTCL | Terminated | 1977 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |